The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Beta cell mass in diabetes: a realistic therapeutic target?
Open accessAbstract
Beta cell deficiency underlies both type 1 and type 2 diabetes, and restoration or replacement of beta cell function is therefore the logical long-term solution to therapy. This review sets out to describe the defects in beta cell mass and function in both forms of diabetes, summarises current understanding of the underlying causes of beta cell death, and the methodological limitations of determining beta cell mass in vivo. Finally, the potential effects of current and future treatment regimens on beta cell mass and turnover are considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regeneration of β-cell function in experimental animal models has been widely observed in rodents but remains elusive and controversial in humans (13,14).”
From Adaptive β-Cell Proliferation Is Severely Restricted With Advanced Age (2009) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“Sadly, expansion of bona fide human β-cells has not been convincingly demonstrated (13–15).”
From Adaptive β-Cell Proliferation Is Severely Restricted With Advanced Age (2009) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Banting lecture 1988. Role of insulin resistance in human disease.
Reaven, G. (1988) · Diabetes · doi:10.2337/diabetes.37.12.1595 · Cited by 3,801
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation
Dor, Y., Brown, J., Martinez, O. I., & Melton, D. A. (2004) · Nature · doi:10.1038/nature02520 · Cited by 2,219
Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells
D’Amour, K. A., Bang, A. G., Eliazer, S., Kelly, O., Agulnick, A. D., Smart, N. G., Moorman, M. A., KROON, E. J., Carpenter, M. K., & Baetge, E. E. (2006) · Nature Biotechnology · doi:10.1038/nbt1259 · Cited by 1,913
Five-Year Follow-Up After Clinical Islet Transplantation
Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., Lakey, J. R. T., & Shapiro, A. M. J. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2060 · Cited by 1,641
Pathologic anatomy of the pancreas in juvenile diabetes mellitus
Gepts, W. (1965) · Diabetes · doi:10.2337/diab.14.10.619 · Cited by 1,345
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Research works printed but not linked: 1
- Meier JJ, Butler PC (2005) Insulin secretion. In: DeGroot LJ, Jameson JL (eds) Endocrinology, 5th edn. Elsevier Saunders, Philadelphia, pp 961–973
Cited by
Sorted by citations
Items 101–154 of 154
A validated LC-MS/MS method for the pharmacokinetic study of alogliptin in healthy rabbits
Ravi, Y., & Rajkamal, B. B. (2019) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2019.90204 · Cited by 7
“Type 2 diabetes is a chronic and progressive disease, characterized by resistance to insulin and malfunction of b-cell (Meier, 2008; Kaneto et al., 2010; Robertson et al., 2004).”
BackgroundTreating type 2 diabetes: incretin mimetics and enhancers
Janosz, K. E. N., Zalesin, K. C., Miller, W. M., & McCullough, P. A. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709341377 · Cited by 7
“Insulin deficiency, insulin resistance and impaired glucose homeostasis initiate this debilitating process, which in turn, promotes beta-cell dysfunction that further limits treatment efficacy [Meier, 2008; Turner et al. 1999].”
BackgroundEndoplasmic Reticulum Stress-induced Transcriptional Factor CHOP and Cardiovascular Diseases
Gotoh, T., Endo, M., & Oike, Y. (2010) · Current Hypertension Reviews · doi:10.2174/157340210790231717 · Cited by 6
Scars of oxidative stress: protein carbonylation and beta cell dysfunction in diabetes
Ling, A., Schultz, K. R., Knight, J. D., Shearn, C. T., & Baumel-Alterzon, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1722623 · Cited by 6
“Despite T1D arising from immune-mediated processes and T2D from metabolic dysfunction, both share a hallmark feature: a profound loss of functional insulin-producing b -cells, driven by mechanisms that are still not fully understood (3 – 5).”
Schønecker, B., Freimanis, T., & Sørensen, I. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022893 · Cited by 5
“called insulitis slowly destroys the insulin-producing beta cells in the islets of Langerhans and probably also results in a reduced function of the remaining islets [25,27].”
BackgroundGrowth Factor Mediated Regulation of Beta Cell Survival
Vasavada, R. C. (2010) · The Open Endocrinology Journal · doi:10.2174/1874216501004010078 · Cited by 5
Dhesi, B., Chauhan, H., & Basu, A. (2013) · Practical Diabetes · doi:10.1002/pdi.1767 · Cited by 4
Ukegjini, K., Müller, P. C., Warschkow, R., Tarantino, I., Petrowsky, H., Gutschow, C. A., Schmied, B. M., & Steffen, T. (2024) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-024-03444-3 · Cited by 4
Chavey, A., Movassat, J., & Porth, B. (2011) · InTech eBooks · doi:10.5772/23027 · Cited by 4
“Indeed, beta-cell mass deficit has been increasingly recognized as a central cause of T2D over the years (Meier, 2008).”
BackgroundShuai, H., Zhang, J., Zhang, J., Xie, J., Zhang, M., Ma, J., Zhang, L., & Wang, X. (2012) · Brain Research · doi:10.1016/j.brainres.2012.08.049 · Cited by 4
Trehalose Protects Islets of Langerhans in HFD-fed Obese Mice: A Morphometric Analysis
Arai, C., Miyata, M., Yoshizane, C., Koide, K., Mizote, A., Arai, N., Hanaya, T., Arai, S., & Fukuda, S. (2013) · Nippon Eiyo Shokuryo Gakkaishi · doi:10.4327/jsnfs.66.17 · Cited by 4
Mukhopadhyay, A., & Prosenjit, M. (2018) · Journal of Clinical and Molecular Endocrinology · doi:10.21767/2572-5432.100047 · Cited by 5
“Hence the quantification and regeneration of beta cell mass is very important to diagnose the diabetic patient and initiate proper treatment [61].”
Noninvasive quantitative evaluation of viable islet grafts using 111In‐exendin‐4 SPECT/CT
Botagarova, A., Murakami, T., Fujimoto, H., Fauzi, M., Kiyobayashi, S., Otani, D., Fujimoto, N., & Inagaki, N. (2023) · The FASEB Journal · doi:10.1096/fj.202201787rr · Cited by 3
Obafemi, T. O., Alfa, J. A., Obafemi, B. A., Jaiyesimi, K. F., Olasehinde, O. R., Adewale, O. B., Akintayo, C. O., & Adu, I. A. (2023) · Comparative Clinical Pathology · doi:10.1007/s00580-023-03528-4 · Cited by 5
“Even though there is inconsistency in the ability of metformin to prevent beta-cell apoptosis (Meier 2008; De-Fronzo and Abdul-Ghani 2011; Page and Reisman 2013), gliclazide was reported to prevent beta-cell apoptosis (Sliwinska et al. 2012).”
Montemurro, C., Köhler, C. U., Uhl, W. H., Tannapfel, A., Schmidt, W. E., Bonora, E., & Meier, J. J. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.07.164 · Cited by 3
“In the present study, we employed this model of endogenous hyperinsulinism to address the following questions: [1] Is there a difference in pancreatic beta-cell area between control tissue and the tumor-free pancreatic tissue of insulinoma patients? [2] Are there differences in beta-cell turnover (apoptosis, replicati…”
InfluentialSelf-citationNext-gen therapeutics to spare and expand beta-cell mass
Bolla, A. M., Usuelli, V., Nasr, M. B., Frigerio, S., Loretelli, C., D’Addio, F., & Fiorina, P. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.001 · Cited by 3
Human beta cell proliferation by glucose—a complex scenario
Tiedge, M. (2010) · Diabetologia · doi:10.1007/s00125-010-2015-2 · Cited by 3
“the release of incretin hormones from the gut [10, 17, 18].”
BackgroundPancreatic beta cell regenerative potential of Zanthoxylum chalybeum Engl. Aqueous stem bark extract
Kimani, C. N., Reuter, H., Kotzé, S. H., Venter, P. B., Ramharack, P., & Muller, C. J. F. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117374 · Cited by 4
Sun, S., Cui, W., Dong, Y., & Wang, Q. (2019) · Macromolecular Research · doi:10.1007/s13233-019-7061-0 · Cited by 3
Titisari, N., Fauzi, A. S., Razak, I. S. A., Samsulrizal, N., & Ahmad, H. (2023) · Open Veterinary Journal · doi:10.5455/ovj.2023.v13.i8.4 · Cited by 3
Rosol, T. J., Braendli-Baiocco, A., Hoenerhoff, M. J., & Vahle, J. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-821046-8.00002-5 · Cited by 4
Type 2 diabetes: the evolution of a disease
Lebovitz, H. E. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412470289 · Cited by 3
Meier, J. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00032-9 · Cited by 3
Self-citationMeier, J. J., & Nauck, M. A. (2020) · Endocrinology · doi:10.1210/endocr/bqaa107 · Cited by 2
Self-citationIslet Endothelium: Role in Type 1 Diabetes and in Coxsackievirus Infections
Favaro, E., Miceli, I., Camussi, E., & Maria, M. (2011) · InTech eBooks · doi:10.5772/24389 · Cited by 1
“In fact, production of the vasoactive mediator NO by islet endothelium (Meier, 2008; Favaro et al., 2008) is increased in hyperglycaemic conditions and has an established direct cytotoxicity on islets and potentially impairs insulin release (Corbett JA et al., 1993).”
InfluentialRegenerative Medicine and Tissue Engineering for the Treatment of Diabetes
Matsumoto, S., SoRelle, J. A., & Shimoda, M. (2011) · InTech eBooks · doi:10.5772/22808 · Cited by 1
Hickman, E., Gillies, C. L., Khunti, K. K., & Seidu, S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.03.005 · Cited by 1
Ogawa, Y., Kimura, H., Fujimoto, H., Kawashima, H., Toyoda, K., Mukai, E., Yagi, Y., Ono, M., Inagaki, N., & Saji, H. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116496 · Cited by 1
Búsqueda de dianas terapeúticas en la célula Beta-Pancreática para el tratamiento de la diabetes
Acosta, J. F. L. (2013) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/4374 · Cited by 1
de Valk, H. W. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.184 · Cited by 1
“Residual beta-cell function is rather limited in insulin-requiring patients with type 2 diabetes [21], and one would suspect that the DPP-4 effect may be influenced by a significant decrease in glucagon levels.”
BackgroundDijabetes melitus u detinjstvu: činjenice i kontroverze
Šaranac, L. (2011) · Paediatrics Today · doi:10.5457/p2005-114.9
β-Zell-Erhalt durch inkretinbasierte Therapien
Menge, B. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0700-5
The Effects of Incretin Mimetics on Islet Cell Function in Type 2 Diabetes
Marchetti, P., & Boggi, U. (2008) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2008.04.02.50
New Therapeutic Approaches to Prevent or Delay Beta-Cell Failure in Diabetes
Ionică, F. E. (2015) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2015-0038
“However, in T1DM, beta-cell loss occurs as a consequence of immune-mediated beta-cell destruction, while in T2DM beta-cell loss is explained mainly by a significant increase in beta-cell apoptosis [3].”
BackgroundGodehardt, A. W., Schilling-Leiß, D., Sanzenbacher, R., & Tönjes, R. R. (2015) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-015-2246-y
4. New Insights of Islet Biology and the Pathophysiology of Type 2 Diabetes
Powers, A. C., & Stein, R. W. (2011) · Translational endocrinology & metabolism · doi:10.1210/team.9781879225824.ch4
Горшунская, М. Ю. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.4.68.2015.75016
Полторак, В. В., Кравчун, Н. А., & Gorshunska, M. (2016) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.7.71.2015.72588
Siddiqa, A., Ahmad, J., Paracha, R. Z., Bibi, Z., & Ali, A. (2018) · Advances in intelligent systems and computing · doi:10.1007/978-3-030-02116-0_49
Nahle, A. (2016) · TSpace (University of Toronto)
Dysfunction and Death of Pancreatic Beta Cells in Type 2 Diabetes
Ortega‐Camarillo, C. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_12
(2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32832eb365
(2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328329fcc2
Meier, J. J., & Butler, P. C. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00033-2
Self-citationThe β-Cell in Human Type 2 Diabetes
Marselli, L., Suleiman, M., Syed, F., Filipponi, F., Boggi, U., Marchetti, P., & Bugliani, M. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_16-2
The β-Cell in Human Type 2 Diabetes
Marselli, L., Suleiman, M., Syed, F., Filipponi, F., Boggi, U., Marchetti, P., & Bugliani, M. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_16
Umaru, I. J., Ahmed, M. U., Habibu, B., Kenneth, I., Philip, S., & Muhammad Zuhairah, I. (2022) · Asian Journal of Biochemistry · doi:10.3923/ajb.2022.7.14
Alipour, M., & Aghazadeh, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85947-9.00005-4 · Cited by 1
Rad, M. G., Dastgerdi, A. H., Rezazadeh, A. H., & Soltani, N. (2021) · Austin Journal of Pharmacology and Therapeutics · doi:10.26420/austinjpharmacolther.2021.1154
Dysfunction and Death of Pancreatic Beta-Cells in Type 2 Diabetes
Ortega‐Camarillo, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_13
MOŽE LI SE TIP 1 DIJABETESA PREVENIRATI ?
Šaranac, L. (2019) · Preventive Paediatrics · doi:10.46793/pp190309003s
Dalton, M., Asante-Asamani, E. O., & Greene, J. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.15.688620
Forcing alpha-cell-mediated beta-cell regeneration
Ben-Othman, N. (2015) · theses.fr (ABES) · doi:10.70675/376c5af0zd161z4a1ez92aez1b3746176067
“…would open new therapeutic possibilities not only for T1DM, characterized by a progressive autoimmune-mediated loss of βcells, but also for TD2M, where a reduction of β-cell mass also occurs in the later stage of the disease (Karalliedde and Gnudi, 2014; Meier, 2008; Prentki and Nolan, 2006).”
Background
Metadata
- Authors
- Meier, J. J.
- Affiliations
- St. Josef-Hospital (DE)
- Corresponding author
- Meier, J. J.
- ORCID
- Meier, J. J.
- Venue
- Diabetologia
- Published
- 2008-03-04
- Volume
- 51
- Issue
- 5
- Pages
- 703-713
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2166312550
- Cited by
- 155
- References
- 104
- Citations by year
- 2025: 3 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 13 · 2014: 11 · 2013: 11 · 2012: 13
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- beta-cell mass, type 1 diabetes, type 2 diabetes, beta-cell death, diabetes treatment
- MeSH terms
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Regeneration, Apoptosis, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
